1. patients with a history of allergy to vc. 2. pregnant or lactating women. 3. patients with end-stage malignant tumour. 4. patients with an expected survival duration of less than 24 hours. 5. patients with cerebral hernia and severe craniocerebral injury. 6. patients with diabetes. 7. patients with a previous history of g-6-pd deficiency.

1. patients with a history of allergy to vc. 2. pregnant or lactating women. 3. patients with end-stage malignant tumour. 4. patients with an expected survival duration of less than 24 hours. 5. patients with cerebral hernia and severe craniocerebral injury. 6. patients with diabetes. 7. patients with a previous history of g-6-pd deficiency.

patients with a history of allergy to vc. pregnant or lactating women. patients with end-stage malignant tumour. patients with an expected survival duration of less than 24 hours. patients with cerebral hernia and severe craniocerebral injury. patients with diabetes. patients with a previous history of g-6-pd deficiency.

patients with a history of allergy to vc. pregnant or lactating women. patients with end-stage malignant tumour. patients with an expected survival duration of less than 24 hours. patients with cerebral hernia and severe craniocerebral injury. patients with diabetes. patients with a previous history of g-6-pd deficiency.